Press release
Hepatitis D Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential
Discover the latest drugs and treatment options in the Hepatitis D Pipeline. Dive into DelveInsight's comprehensive report today! @ Hepatitis D Pipeline Outlook [https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Hepatitis D Pipeline Report
* On 10 September 2025, Huahui Health conducted a phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus. This study aims to assess efficacy and safety in subjects with chronic hepatitis delta virus infection.
* On 05 September 2025, Gilead Sciences conducted a clinical study are to first learn more about safety and dosing of the study drug GS-4321 in healthy participants. The study will then learn about the safety and effectiveness of GS-4321 in participants with chronic hepatitis delta (CHD).
* DelveInsight's Hepatitis D Pipeline report depicts a robust space with 8+ active players working to develop 10+ pipeline therapies for Hepatitis D treatment.
* The leading Hepatitis D Companies such as Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.
* Promising Hepatitis D Pipeline Therapies such as Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others.
Stay ahead with the most recent pipeline outlook for Hepatitis D. Get insights into clinical trials, emerging therapies, and leading companies with Hepatitis D @ Hepatitis D Treatment Drugs [https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hepatitis D Emerging Drugs Profile
* Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals
Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen. It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes, and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart, which incorporates Xencor's Xtend Trademark and other Fc technologies, has been engineered to have an extended half-life and was identified using Vir Biotechnology's proprietary monoclonal antibody discovery platform. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicates that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. It is the first asset in Vir Biotechnology's collaboration with Alnylam Pharmaceuticals, Inc. to enter clinical studies. Currently, this combination drug product is in Phase III stage of its development for the treatment of Hepatitis D.
* Brelovitug: Bluejay Therapeutics
Brelovitug is an investigational, highly potent, pan-genotypic, fully human IgG1 mAb that targets the anti-HBsAg on both the HDV and the HBV. Brelovitug is designed to neutralize and remove hepatitis B and hepatitis D virions and deplete HBsAg-containing subviral particles, which gives brelovitug a potentially advantageous safety profile and makes it a potentially efficacious treatment for CHD, a condition with urgent unmet medical need. In addition, brelovitug has shown immunomodulatory functions in CHB patients, which may help to reconstitute antiviral immunity and contribute to functional cure for CHB when combined with other agents. Currently, the drug is in the Phase II/III stage of its development for the treatment of Hepatitis D.
* RBD1016: Ribocure Pharmaceuticals AB
RBD1016 is a GalNAc-siRNA drug independently developed by Ribo based on its proprietary GalNAc-siRNA platform, targeting the X gene of hepatitis B virus. It inhibits all four HBV transcripts through the RNA interference mechanism, and can simultaneously inhibit HBV DNA replication, reduce cccDNA and integrate DNA derived HBsAg and other antigens. RBD1016 demonstrates well-tolerated safety profile in Phase I study including both healthy subjects and patients with CHB infection. RBD1016 shows a highly efficient long-acting effect of reducing the HBsAg in patients. Currently, the drug is in Phase II stage of its development for the treatment of Hepatitis D.
The Hepatitis D Pipeline Report Provides Insights into-
* The report provides detailed insights about companies that are developing therapies for the treatment of Hepatitis D with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D Treatment.
* Hepatitis D Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Hepatitis D Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Hepatitis D market
Explore groundbreaking therapies and clinical trials in the Hepatitis D Pipeline. Access DelveInsight's detailed report now! @ New Hepatitis D Drugs [https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Hepatitis D Companies
Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.
Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Hepatitis D Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Unveil the future of Hepatitis D Treatment. Learn about new drugs, Hepatitis D Pipeline developments, and key companies with DelveInsight's expert analysis @ Hepatitis D Market Drivers and Barriers [https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Hepatitis D Pipeline Report
* Coverage- Global
* Hepatitis D Companies- Vir Biotechnology, Inc./Alnylam Pharmaceuticals, Bluejay Therapeutics, Inc., Ribocure Pharmaceuticals AB, Assembly Biosciences, Shanghai HEP Pharmaceutical Co., Ltd., Huahui Health and others.
* Hepatitis D Pipeline Therapies- Brelovitug 300 mg, lonafarnib, Ritonavir, Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa), hepalatide, Peginterferon Lambda-1a and others.
* Hepatitis D Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Hepatitis D Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Get the latest on Hepatitis D Pipeline Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ Hepatitis D Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/hepatitis-d-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Contents
* Introduction
* Executive Summary
* Hepatitis D: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Hepatitis D- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Tobevibart + Elebsiran: Vir Biotechnology/ Alnylam Pharmaceuticals
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II/III)
* Brelovitug: Bluejay Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Inactive Products
* Hepatitis D Key Companies
* Hepatitis D Key Products
* Hepatitis D- Unmet Needs
* Hepatitis D- Market Drivers and Barriers
* Hepatitis D- Future Perspectives and Conclusion
* Hepatitis D Analyst Views
* Hepatitis D Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hepatitis-d-pipeline-outlook-2025-insights-into-therapies-research-and-market-potential]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/hepatitis-d-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hepatitis D Pipeline Outlook 2025: Insights Into Therapies, Research, and Market Potential here
News-ID: 4178164 • Views: …
More Releases from ABNewswire
Psoriasis Market: Epidemiology, Therapies, and Companies, DelveInsight | Featuri …
The Psoriasis therapeutics market report provides current treatment practices, emerging psoriasis drugs, psoriasis market share of individual therapies, and current and forecasted 7MM Psoriasis market size from 2020 to 2034. The psoriasis market report also covers current Psoriasis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the psoriasis market underlying potential.
Psoriasis companies are LEO Pharma, Promius Pharma, Mayne Pharma, Bausch Health Companies, MC2 Therapeutics, Bristol-Myers…
Autoimmune Encephalitis Market: Epidemiology, Therapies, Companies, DelveInsight …
Autoimmune Encephalitis market report provides real-world prescription pattern analysis, emerging drugs, market share of individual therapies, and historical and forecasted 7MM Autoimmune Encephalitis market size from 2020 to 2034. The report also covers current Autoimmune Encephalitis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's underlying potential.
Emerging therapies for Autoimmune Encephalitis, including Satralizumab, GLOVENIN-I (TAK-961), and others, are expected to drive growth in the…
IgA Nephropathy Pipeline 2025: Innovative Clinical Developments by 30+ Leading G …
DelveInsight's, "IgA Nephropathy Pipeline Insight, 2025," report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The IgA Nephropathy (IgAN) market is being propelled by several key…
Autoimmune Psychosis Market: Epidemiology, Treatments, and Key Players, DelveIns …
The autoimmune psychosis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM autoimmune psychosis market size from 2020 to 2034. The report also covers autoimmune psychosis treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.
Emerging therapies for Autoimmune Psychosis, including ENSPRYNG (satralizumab, RG6168), ART5803, and others, are expected to drive growth in the Autoimmune…
More Releases for Hepatitis
Driving Viral Hepatitis Market Growth in 2025: The Role of Elevated Prevalence O …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
Viral Hepatitis Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the size of the viral hepatitis market has experienced consistent growth. It is projected to increase from $16.21 billion in 2024 to $16.93 billion in 2025, representing a compound annual growth rate (CAGR)…
Elevated Prevalence Of Hepatitis Driving Growth In The Viral Hepatitis Market: A …
The Viral Hepatitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Viral Hepatitis Market Size and Its Estimated Growth Rate?
In the past few years, there has been a consistent increase in the size of the viral hepatitis market. It is predicted…
Elevated Prevalence Of Hepatitis Driving Growth In The Viral Hepatitis Market: A …
The Viral Hepatitis Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Current Viral Hepatitis Market Size and Its Estimated Growth Rate?
In the past few years, there has been a consistent increase in the size of the viral hepatitis market. It is predicted…
Key Influencer in the Hepatitis B Virus (HBV) Market 2025: Rising Hepatitis B In …
Which drivers are expected to have the greatest impact on the over the hepatitis b virus (hbv) market's growth?
The escalated incidence rates of hepatitis B infection are anticipated to contribute significantly to the future expansion of the hepatitis B virus market. Hepatitis B is a liver-related infection that is triggered by the hepatitis B virus (HBV), and can be avoided through vaccination. The surge in hepatitis B infection rates could…
Hepatitis D Market - Defeating Hepatitis D Together: Uniting Against the Silent …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Hepatitis D Market.
Hepatitis D Market: https://www.growthplusreports.com/report/hepatitis-d-market/9196
The Hepatitis D Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production strategy.…
Hepatitis C Testing Market - Advancing Hepatitis C Elimination Strategies: Embra …
Newark, New Castle, USA: The "Hepatitis C Testing Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Hepatitis C Testing Market: https://www.growthplusreports.com/report/hepatitis-c-testing-market/7962
This latest report researches the industry structure,…
